Overview
See Epithalon entry for core data. In the context of sleep physiology, Epithalon's primary pineal mechanism involves restoration of circadian melatonin release patterns that decline with aging. Research by Khavinson and colleagues has shown that Epithalon supplementation in elderly subjects restores night-time melatonin surges toward youthful levels, normalizes the circadian pattern of cortisol, and improves overall sleep architecture. This pineal bioregulation is considered central to Epithalon's anti-aging effects, as melatonin orchestrates multiple repair and restoration processes during sleep.
Mechanism of Action
Epithalon upregulates pinealocyte sensitivity to circadian photic input, restoring the amplitude of nighttime melatonin secretion that diminishes with age. Melatonin in turn regulates the master circadian clock via MT1/MT2 receptors in the suprachiasmatic nucleus. Restoration of melatonin rhythm improves sleep architecture, particularly slow-wave sleep duration, and synchronizes peripheral circadian clocks in metabolic tissues. The cortisol circadian curve also normalizes, reducing nighttime cortisol elevation that disrupts sleep quality.
Potential Benefits
- Restoration of circadian melatonin secretion amplitude
- Improved sleep architecture, particularly slow-wave sleep
- Normalization of cortisol circadian rhythm
- Integration with broader anti-aging effects of Epithalon
- Non-addictive sleep improvement mechanism
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 5 mg daily for 10 days, once yearly |
| Intermediate | 10 mg daily for 10 days, every 6-12 months |
| Advanced | 10 mg daily for 20 days, every 6 months |
| Cycle Duration | 10-20 days, repeat every 6-12 months |
Same molecule as Epithalon (Ala-Glu-Asp-Gly). Extended-protocol dosing in Khavinson research.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Standard Khavinson bioregulator route.
Intramuscular Injection High
Sometimes used in Russian clinical protocols.
Intranasal Moderate
Less common but used for CNS effects.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Epitalon (Extended):
Extended Longevity Protocol
Long-term Khavinson bioregulator rotation — telomere/pineal + immune + cognitive support over 20-day courses.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 5-20 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Ala-Glu-Asp-Gly (same as Epithalon)
Side Effects & Safety
- See Epithalon entry
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Epitalon (Extended) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.